Molecular Partners Ag Stock Today
| MOLN Stock | USD 3.70 0.18 4.64% |
Performance0 of 100
| Odds Of DistressLess than 21
|
Molecular Partners is selling at 3.70 as of the 30th of April 2024; that is -4.64 percent down since the beginning of the trading day. The stock's open price was 3.88. Molecular Partners has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Molecular Partners AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of May 2022 and ending today, the 30th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of June 2021 | Category Healthcare | Classification Health Care |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Molecular Partners operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 32.87 M outstanding shares of which 56.35 K shares are now shorted by private and institutional investors with about 12.93 trading days to cover. More on Molecular Partners AG
Moving together with Molecular Stock
| 0.75 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
Moving against Molecular Stock
| 0.84 | HCM | HUTCHMED DRC | PairCorr |
| 0.51 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
| 0.51 | BHC | Bausch Health Companies Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | ACB | Aurora Cannabis Downward Rally | PairCorr |
| 0.46 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 10th of May 2024
Molecular Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Molecular Partners' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Molecular Partners or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Computers, Biotech, Health Management, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Molecular Partners report their recommendations after researching Molecular Partners' financial statements, talking to executives and customers, or listening in on Molecular Partners' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Molecular Partners. The Molecular consensus assessment is calculated by taking the average forecast from all of the analysts covering Molecular Partners. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Molecular Partners' liquidity, profitability, solvency, and operating efficiency, Molecular Partners AG may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Molecular Partners is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Partners' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Molecular Partners' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Molecular Partners' financial leverage. It provides some insight into what part of Molecular Partners' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Partners AG (MOLN) is traded on NASDAQ Exchange in USA. It is located in Wagistrasse 14, Schlieren, Switzerland, 8952 and employs 167 people. Molecular Partners is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 118.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molecular Partners's market, we take the total number of its shares issued and multiply it by Molecular Partners's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Molecular Partners conducts business under Biotechnology sector and is part of Health Care industry. The entity has 32.87 M outstanding shares of which 56.35 K shares are now shorted by private and institutional investors with about 12.93 trading days to cover.
Molecular Partners AG currently holds about 267.13 M in cash with (55.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Molecular Partners Probability Of Bankruptcy
Ownership AllocationMolecular Partners maintains a total of 32.87 Million outstanding shares. Roughly 97.0 % of Molecular Partners outstanding shares are held by general public with 2.63 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Molecular Ownership Details
Molecular Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Molecular Partners jumping above the current price in 90 days from now is more than 93.0%. The Molecular Partners AG probability density function shows the probability of Molecular Partners stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Molecular Partners has a beta of 0.0486. This indicates as returns on the market go up, Molecular Partners average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Molecular Partners AG will be expected to be much smaller as well. Additionally, molecular Partners AG has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Molecular Partners to move above the current price in 90 days from now is more than 93.0 (This Molecular Partners AG probability density function shows the probability of Molecular Stock to fall within a particular range of prices over 90 days) .
Molecular Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Molecular Partners that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Molecular Partners' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Molecular Partners' value.| Instituion | Recorded On | Shares | |
| Bvf Inc | 2023-09-30 | 443.2 K | |
| Suvretta Capital Management, Llc | 2023-12-31 | 400 K | |
| Tang Capital Management Llc | 2023-09-30 | 100 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 12.6 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 367 | |
| Rhumbline Advisers | 2023-12-31 | 269 | |
| Qube Research & Technologies | 2023-12-31 | 16.0 | |
| Jpmorgan Chase & Co | 2023-12-31 | 1.0 | |
| Jane Street Group, Llc | 2023-09-30 | 0.0 |
Molecular Partners Historical Income Statement
Molecular Partners AG Income Statement is one of the three primary financial statements used for reporting Molecular's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Molecular Partners revenue and expense. Molecular Partners Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Molecular Partners' Net Interest Income is very stable compared to the past year. As of the 30th of April 2024, Interest Income is likely to grow to about 4 M, while Depreciation And Amortization is likely to drop about 2.1 M. View More FundamentalsMolecular Stock Against Markets
Picking the right benchmark for Molecular Partners stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Molecular Partners stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Molecular Partners is critical whether you are bullish or bearish towards Molecular Partners AG at a given time. Please also check how Molecular Partners' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Molecular Partners without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Molecular Partners Corporate Management
Elected by the shareholders, the Molecular Partners' board of directors comprises two types of representatives: Molecular Partners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Molecular. The board's role is to monitor Molecular Partners' management team and ensure that shareholders' interests are well served. Molecular Partners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Molecular Partners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Hendriks | Senior Finance | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Michael Pitzner | Compliance Counsel | Profile | |
| MD MBA | Interim Officer | Profile | |
| Daniel Steiner | Senior Technology | Profile | |
| Anne DVM | Senior Development | Profile |
How to buy Molecular Stock?
Before investing in Molecular Partners, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Molecular Partners. To buy Molecular Partners stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Molecular Partners. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Molecular Partners stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Molecular Partners AG stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Molecular Partners AG stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Molecular Partners AG, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Molecular Stock please use our How to Invest in Molecular Partners guide.
Already Invested in Molecular Partners AG?
The danger of trading Molecular Partners AG is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Molecular Partners is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Molecular Partners. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Molecular Partners is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Revenue Per Share 0.215 | Quarterly Revenue Growth (0.62) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.